Abstract

PREVENTION OF DT-010 ON DOXORUBICIN INDUCED CARDIOTOXICITY IN RATS

Jia Wu, Caipeng Xie, Huihui Hu, Pei Yu, Yuqiang Wang and Luchen Shan*

ABSTRACT

Doxorubicin-induced cardiac toxicity is considered as the main restriction of its clinical application. In this study, we aimed to investigate the effect of a novel compound DT-010 on doxorubicin cardiotoxicity in rats. SD male rats were divided into three groups as following control group, doxorubicin (DOX) group and DT-010 treatment group. Rats were intravenously injected doxorubicin at a dose of 2.5 mg/kg once a week for 5 consecutive weeks to induce cardiotoxicity. The heart function was examined by echocardiography, and the heart was collected for Western blot and histopathological analysis. The results showed that DT-010 delayed weight loss and death of rats caused by DOX, improved the cardiac contractility, and attenuated the pathological lesions of myocardial tissue. DT-010 lowered the ratio of Cleaved Caspase-3/Caspase-3 in rat hearts, suggesting that DT-010 could inhibit DOX-induced apoptosis. In conclusion, the present study showed DT-010’s cardioprotective effect against doxorubicin-induced cardiotoxicity, and DT-010 will be a potential candidate for prevention of doxorubicin-induced cardiotoxicity.

Keywords: Danshensu/Ligustrazine derivatives, doxorubicin-induced cardiotoxicity, cardioprotection.